US · BDSX
Biodesix, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Boulder, CO 80301
- Website
- biodesix.com
Price · as of 2025-12-31
$11.08
Market cap 121.96M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $89.00 | +703.25% |
| Intrinsic Value(DCF) | $36.17 | +226.44% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $456.00 | $202.15 | $65,972.32 | $0.00 | $0.00 |
| 2021 | $44.80 | $30.84 | $122.16 | $0.00 | $0.00 |
| 2022 | $31.40 | $19.66 | $0.00 | $0.00 | $633.40 |
| 2023 | $29.60 | $136.88 | $0.00 | $0.00 | $0.00 |
| 2024 | $17.24 | $43.55 | $68.13 | $0.00 | $0.00 |
| 2025 | $15.75 | $89.00 | $25.54 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Biodesix, Inc.'s (BDSX) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $89.00
- Current price
- $11.08
- AI upside
- +703.25%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$36.17
+226.44% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BDSX | Biodesix, Inc. | $11.08 | 121.96M | +703% | +226% | — | — | -3.37 | -48.25 | 1.34 | -7.90 | — | -5.56 | 75.25% | -31.50% | -39.85% | -383.09% | -51.61% | -38.18% | -29.56 | -3.61 | 1.86 | 1.61 | -2.46 | -2924.00% | 2408.00% | -5464.00% | -19.79% | -1.33 | -43.57% | 0.00% | 0.00% | 0.42% | -6.20 | -7.34 | 1.95 | -7.01 |
| ALGS | Aligos Therapeutics, Inc. | $7.03 | 43.26M | -26% | -26% | — | +18,737% | -0.62 | -2.80 | 20.55 | -0.38 | -0.12 | -2.80 | 100.00% | -2259.92% | -3326.01% | -415.84% | 162.06% | -118.41% | -0.29 | — | 2.86 | 2.62 | 0.33 | 49489.00% | -7460.00% | 235.00% | -99.76% | -3.71 | 147.01% | 0.00% | 0.00% | 0.00% | -0.36 | -0.40 | 8.24 | -15.30 |
| INMB | INmune Bio, Inc. | $1.29 | 34.29M | +2,143% | +149% | — | +12,808% | -3.80 | 4.98 | 11425.06 | -3.31 | -14.43 | 10.26 | 100.00% | -304535.71% | -300585.71% | -119.83% | -351.09% | -87.16% | 0.01 | — | 3.14 | 3.09 | 0.49 | 2635.00% | -9097.00% | 17847.00% | -20.86% | -4.62 | -274.72% | 0.00% | 0.00% | 0.00% | -3.27 | -4.18 | 9958.06 | 4.00 |
| MRSN | Mersana Therapeutics, Inc… | $29.08 | 145.36M | +85% | +9,159% | — | — | -0.96 | -7.01 | 1.65 | 0.62 | — | -7.01 | 95.98% | -181.09% | -170.86% | -505.14% | 57.77% | -37.33% | -3.01 | -18.93 | 2.19 | 2.16 | 1.25 | -6180.00% | 988.00% | -5178.00% | -123.65% | -1.32 | 64.97% | 0.00% | 0.00% | 0.00% | 0.54 | 0.48 | -0.97 | -9.18 |
| NOTV | Inotiv, Inc. | $0.27 | 9.31M | +5,205% | +18% | — | — | -0.38 | 0.19 | 0.05 | 20.53 | — | -0.13 | 12.68% | -6.02% | -13.38% | -44.78% | -3.99% | -8.84% | 3.70 | -0.55 | 0.35 | 0.21 | 19.47 | -4964.00% | 454.00% | -702.00% | -102.98% | -0.02 | -4.47% | 0.00% | 0.00% | 0.00% | -16.44 | -18.77 | 0.99 | -1.15 |
| OKUR | OnKure Therapeutics, Inc. | $2.71 | 36.72M | — | — | — | — | -1.27 | 0.64 | — | 0.83 | -2.59 | 0.64 | 0.00% | — | — | -5304.43% | 79.46% | -69.93% | 0.01 | -181.29 | 10.73 | 10.52 | 2.12 | 4906.00% | — | 4707.00% | -76.41% | -4.85 | 74.76% | 0.00% | 0.00% | 120.18% | 0.79 | 0.83 | — | 1.25 |
| PDSB | PDS Biotechnology Corpora… | $0.68 | 36.94M | — | — | — | — | -1.19 | 2.36 | — | -0.74 | — | 2.36 | 0.00% | — | — | -166.65% | 954.97% | -71.81% | 1.15 | -7.77 | 2.64 | 2.44 | 0.59 | -2590.00% | — | 423.00% | -78.19% | -2.05 | 943.09% | 0.00% | 0.00% | 0.00% | -0.69 | -0.71 | — | -6.50 |
| SKYE | Skye Bioscience, Inc. | $0.74 | 23.88M | — | — | — | — | -3.61 | 1.41 | — | -1.11 | — | 1.41 | 0.00% | — | — | -80.48% | -4256.79% | -62.73% | 0.01 | -31.20 | 16.32 | 15.77 | 2.69 | -8641.00% | — | 9221.00% | -27.97% | -5.82 | -3784.31% | 0.00% | 0.00% | 74.32% | -0.93 | -1.04 | — | 9.69 |
| WGRX | Wellgistics Health, Inc. | $0.24 | 16.73M | — | — | — | — | -21.74 | 22.14 | 8.22 | -35.27 | -18.64 | -4.68 | 9.75% | -33.90% | -37.82% | -357.65% | -42.95% | -23.78% | 3.73 | -7.39 | 0.40 | 0.13 | -4.90 | 11667.00% | — | 35893.00% | -1.07% | -0.03 | -11.20% | 0.00% | 0.00% | 0.00% | -28.18 | -108.07 | 9.55 | 1.01 |
| XLO | Xilio Therapeutics, Inc. | $0.53 | 27.74M | — | — | — | — | -0.84 | 2.76 | 7.67 | -0.03 | — | 2.76 | 100.00% | -954.95% | -918.05% | -214.02% | 466.54% | -88.24% | 0.46 | -605.82 | 2.21 | 2.03 | 0.81 | -6079.00% | — | -7335.00% | -37.86% | -0.67 | 141.80% | 0.00% | 0.00% | 28.58% | -0.02 | -0.08 | 0.24 | -9.18 |
About Biodesix, Inc.
Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also offers GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a 72-hour blood-based NGS test. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.
- CEO
- Scott Hutton
- Employees
- 273
- Beta
- 0.68
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($36.17 ÷ $11.08) − 1 = +226.44% (DCF, example).